PATH-29. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BACKGROUNDDepatuxizumab mafodotin (depatux-m, formerly ABT-414), is an EGFR-targeted antibody conjugated to the antimicrotubule agent monomethylauristatin F (MMAF). In an ongoing Phase I study, response in recurrent glioblastoma (rGBM) correlated with EGFR amplification in pre-treatment, archival tumor tissue. However, the correlation with efficacy is imperfect, prompting a search for other biomarkers that predict benefit or resistance, including attention to mutations that could impact sensitivity to the microtubule inhibitor of the depatux-m molecule.